A novel trial methodology to test interventions with very large effect sizes: the case of dostarlimab in mismatch repair-deficient, locally advanced rectal cancer

Dostarlimab (Jemperli, GlaxoSmithKline) is an anti-programmed death receptor-1 monoclonal antibody (anti-PD-1) recently tested in a non-randomized, phase II trial (NCT04165772) which included patients with mismatch repair-deficient, locally advanced rectal cancer. Among the first 12 patients treated...

Descripción completa

Detalles Bibliográficos
Autores principales: Powell, Kerrington, Olivier, Timothée, Prasad, Vinay
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2022
Materias:
Commentary
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789610/
https://www.ncbi.nlm.nih.gov/pubmed/36564825
http://dx.doi.org/10.1186/s13063-022-06988-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9789610/
https://www.ncbi.nlm.nih.gov/pubmed/36564825
http://dx.doi.org/10.1186/s13063-022-06988-1

Ejemplares similares